{"id":"b7h3","name":"B7-H3","symbol":"CD276","route":"/targets/b7h3/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19137","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103855","uniprot":"https://www.uniprot.org/uniprotkb/Q5ZPR3/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q5ZPR3","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712879","open-targets":"https://platform.opentargets.org/target/ENSG00000103855","civic":"https://civicdb.org/genes/80381/summary","oncokb":"https://www.oncokb.org/gene/CD276","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD276","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD276","depmap":"https://depmap.org/portal/gene/CD276?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000103855-CD276","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/80381","omim":"https://www.omim.org/entry/605715"}],"products":[{"id":"bcb-276","name":"BCB-276","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/bcb-276/"},{"id":"bnt324","name":"BNT324","status":"phase-3","modality":"ADC","route":"/drugs/bnt324/"},{"id":"ifinatamab-deruxtecan","name":"Ifinatamab deruxtecan","status":"phase-3","modality":"ADC","route":"/drugs/ifinatamab-deruxtecan/"},{"id":"qlc5508","name":"QLC5508","status":"phase-3","modality":"ADC","route":"/drugs/qlc5508/"},{"id":"yl201","name":"YL201","status":"phase-3","modality":"ADC","route":"/drugs/yl201/"}],"trials":[{"id":"nct06925737","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","nct":"NCT06925737","phase":"3","status":"recruiting"},{"id":"taishan-301","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","nct":"NCT06629597","phase":"3","status":"active"},{"id":"nct06612151","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","nct":"NCT06612151","phase":"3","status":"active"},{"id":"nct07365995","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","nct":"NCT07365995","phase":"3","status":"recruiting"},{"id":"nct07802821","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","nct":"NCT07802821","phase":"3","status":"planned"},{"id":"nct06644781","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","nct":"NCT06644781","phase":"3","status":"recruiting"},{"id":"nct06954246","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","nct":"NCT06954246","phase":"3","status":"recruiting"},{"id":"nct07739758","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","nct":"NCT07739758","phase":"3","status":"recruiting"},{"id":"nct07803783","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","nct":"NCT07803783","phase":"3","status":"planned"},{"id":"ideate-lung02","name":"IDeate-Lung02","nct":"NCT06203210","phase":"3","status":"recruiting"},{"id":"nct07463573","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","nct":"NCT07463573","phase":"3","status":"recruiting"},{"id":"nct06241846","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","nct":"NCT06241846","phase":"2","status":"recruiting"},{"id":"nct06780085","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","nct":"NCT06780085","phase":"2","status":"recruiting"},{"id":"nct06953089","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","nct":"NCT06953089","phase":"2","status":"recruiting"},{"id":"nct05280470","name":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","nct":"NCT05280470","phase":"2","status":"active"},{"id":"nct07680439","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","nct":"NCT07680439","phase":"2","status":"recruiting"},{"id":"nct07227597","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","nct":"NCT07227597","phase":"1/2","status":"recruiting"},{"id":"nct06863272","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","nct":"NCT06863272","phase":"1/2","status":"recruiting"},{"id":"nct07198633","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","nct":"NCT07198633","phase":"1/2","status":"recruiting"},{"id":"nct06892548","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","nct":"NCT06892548","phase":"1/2","status":"recruiting"},{"id":"nct05914116","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","nct":"NCT05914116","phase":"1/2","status":"recruiting"},{"id":"nct04471727","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","nct":"NCT04471727","phase":"1/2","status":"active"},{"id":"nct06362252","name":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","nct":"NCT06362252","phase":"1/2","status":"recruiting"},{"id":"nct07630974","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","nct":"NCT07630974","phase":"1/2","status":"recruiting"},{"id":"nct07126665","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","nct":"NCT07126665","phase":"1/2","status":"recruiting"},{"id":"nct07256782","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","nct":"NCT07256782","phase":"1/2","status":"recruiting"},{"id":"nct07208773","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","nct":"NCT07208773","phase":"1/2","status":"recruiting"},{"id":"nct07407933","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","nct":"NCT07407933","phase":"1/2","status":"recruiting"},{"id":"nct07258979","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","nct":"NCT07258979","phase":"1/2","status":"recruiting"},{"id":"nct05434234","name":"A Study of YL201 in Patients With Advanced Solid Tumors","nct":"NCT05434234","phase":"1/2","status":"recruiting"},{"id":"nct06330064","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","nct":"NCT06330064","phase":"1/2","status":"recruiting"},{"id":"nct06780137","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","nct":"NCT06780137","phase":"1/2","status":"recruiting"},{"id":"nct06057922","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","nct":"NCT06057922","phase":"1/2","status":"active"},{"id":"nct04165070","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","nct":"NCT04165070","phase":"1/2","status":"recruiting"},{"id":"nct04145622","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","nct":"NCT04145622","phase":"1/2","status":"recruiting"},{"id":"nct07102004","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","nct":"NCT07102004","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["aktis-oncology","biontech","daiichi-sankyo","dualitybio","medilink","merck","myricx-bio","qilu-pharmaceutical"],"keyPapers":[],"hotspots":[],"openQuestions":[{"id":"b7h3-selection","question":"Does B7-H3 expression predict benefit from ifinatamab deruxtecan in small-cell lung cancer and prostate cancer, or is it another ADC given without a biomarker?","stage":"translational","actor":"industry","source":{"label":"IDeate-Lung02 (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT06203210"}}],"assays":[],"resistance":[{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}